Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
15 hedge funds and large institutions have $1.24M invested in Titan Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 11 closing their positions.
239% more call options, than puts
Call options by funds: $624K | Put options by funds: $184K
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
36% more capital invested
Capital invested by funds: $909K → $1.24M (+$331K)
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
42% less funds holding
Funds holding: 26 → 15 (-11)
91% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$178K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$42.7K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$10.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$7.77K |
| 5 |
Morgan Stanley
New York
|
+$4.86K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$58K |
| 2 |
VF
Virtu Financial
New York
|
-$53K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$22.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20.4K |
| 5 |
WPA
Winning Points Advisors
Boca Raton,
Florida
|
-$10.7K |
TTNP Hedge Fund Activity: Q1 2019 in Review
15 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q1 2019, worth a combined $1.24M — up 36% from $909K a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TTNP and 1 opened new positions — a net loss of 10 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $178K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $58K sold.
- 15 institutional investors held Titan Pharmaceuticals (TTNP) as of Q1 2019, down from 26 in Q4 2018.
- Funds reported $1.24M of Titan Pharmaceuticals stock for Q1 2019, up 36% quarter-over-quarter.
- 1 fund opened new Titan Pharmaceuticals positions in Q1 2019 and 11 closed out, a net change of -10 holders.
- The largest Titan Pharmaceuticals buyer in Q1 2019 was Vanguard Group, an estimated $178K added.
- The largest Titan Pharmaceuticals seller in Q1 2019 was Renaissance Technologies, an estimated $58K sold.
Based on aggregated 13F filings for Q1 2019.